unit
statesjapan
cooper
medic
scienc
program
usjcmsp
form
joint
issu
us
presid
lyndon
b
johnson
japanes
prime
minist
eisaku
sato
expand
cooper
research
effort
medic
scienc
focu
biomed
need
asian
countri
pacif
rim
usjcmsp
initi
concentr
cholera
leprosi
parasit
diseas
tuberculosi
viral
diseas
area
form
panel
includ
us
japanes
scientist
focu
evolv
time
reflect
chang
public
health
issu
region
current
nine
panel
concentr
acut
respiratori
infect
ari
acquir
immunodefici
syndrom
aid
cancer
cholera
bacteri
enter
infect
hepat
mycobacteri
diseas
nutrit
metabol
parasit
diseas
viral
diseas
separ
crosscut
board
focus
immunolog
usjcmsp
launch
confer
seri
call
intern
confer
emerg
infecti
diseas
eid
pacif
rim
typic
held
annual
differ
countri
region
tabl
confer
particip
exchang
inform
idea
share
current
research
vari
diseas
import
asiapacif
region
intent
foster
research
collabor
follow
eid
confer
specif
panelsboard
hold
meet
focu
confer
altern
yearli
viral
diseas
bacteri
parasit
diseas
mark
anniversari
confer
seri
intern
confer
eid
pacif
rim
held
januari
follow
panelboard
meet
januari
confer
took
place
coli
hotel
shenzhen
peopl
republ
china
local
host
shenzhen
third
peopl
hospit
chines
academi
scienc
ca
institut
microbiolog
report
summar
present
includ
latest
progress
gap
variou
field
research
discuss
conclus
confer
usjcmsp
collabor
award
initi
establish
follow
anniversari
program
support
new
expand
infecti
diseas
immunolog
research
collabor
research
japan
asiapacif
region
unit
state
initi
also
promot
facilit
inclus
earlystag
femal
investig
collabor
research
region
eid
confer
provid
platform
award
recipi
highlight
collabor
research
brief
talk
poster
present
session
focus
recent
trend
viral
infect
asia
pacif
rim
session
aim
review
import
new
longtim
reemerg
infecti
viral
threat
asia
consid
research
public
health
respons
need
address
inform
provid
newli
recogn
viral
infect
eg
hemorrhag
fever
viru
cchfv
previous
underappreci
epidemiolog
wellknown
viral
infect
eg
hepat
virus
well
highlight
seriou
viru
outbreak
current
public
eye
eg
dengu
zika
avian
influenza
first
present
focus
threat
avian
influenza
viru
current
caus
zoonot
infect
mostli
acquir
live
bird
market
one
rest
day
closur
poultri
market
signific
impact
reduc
viru
persist
transmiss
viru
aerosol
poultri
handl
defeath
area
report
case
influenza
underestim
extent
human
infect
effect
vaccin
need
studiedhepat
anoth
talk
report
endem
preval
hepat
virus
mongolia
highest
rate
liver
cancer
mortal
world
time
global
averag
high
preval
mostli
healthsystem
driven
use
dirti
needl
improp
steril
dental
equip
inject
drug
abus
also
contribut
sixti
percent
hepat
b
viru
hbv
infect
mongol
coinfect
hepat
delta
viru
hdv
govern
mongolia
adopt
plan
includ
screen
everi
citizen
hepat
viru
infect
prevent
control
eventu
elimin
hepat
mongoliadengu
overview
dengu
public
health
prioriti
region
present
distribut
dengu
widespread
inflict
high
medic
cost
burden
pathogenesi
dengu
viru
infect
remain
unclear
pitfal
diagnosi
manag
diseas
shift
epidemiolog
infect
diseas
move
rural
areaszika
present
current
state
zika
viru
zikv
epidemiolog
provid
zikv
amplifi
much
frequent
virus
aed
aegypti
aed
albopictu
mosquito
particularli
africa
strain
seen
transmit
much
effici
aed
aegypti
evid
primat
intermedi
transmiss
sever
differ
topic
discuss
zikv
includ
associ
zikv
infect
microcephali
guillainbarr
syndrom
zikv
arriv
america
whether
chikungunya
dengu
viru
infect
provid
insight
zikv
infect
america
sever
studi
fail
provid
evid
immun
enhanc
although
question
remain
dengu
viru
immun
affect
zikv
infect
vice
versa
evolut
urban
transmiss
also
consid
emerg
differ
viru
hemorrhag
fever
cchf
expans
cchf
asia
review
cchfv
orthonairoviru
transmit
bite
tick
hyalomma
marginatum
incub
period
infect
day
death
occur
day
reassort
gene
among
cchf
virus
lead
new
strain
new
diseas
mani
countri
report
increas
number
case
may
due
infect
tick
amplif
migratori
bird
live
anim
trade
increas
tick
activ
observ
eid
festiv
coincid
backyard
slaughter
anim
increas
human
infect
session
focus
pathogenesi
emerg
viral
infect
affect
southeast
asian
countri
diverg
mechan
hepat
c
first
talk
session
compar
level
immun
marker
antivir
treatment
hepat
c
viru
hcv
infect
found
level
lower
treatmentcoronaviru
next
present
share
coronavirus
exoribonucleas
exon
play
key
role
maintain
low
mutat
rate
viru
exon
delet
increas
mutat
rate
well
attenu
pathogenesisenteroviru
talk
focus
carri
variant
mainli
respons
develop
viremia
neuropathogenesi
nonhuman
primat
model
suggest
involv
amino
acid
polymorph
cellspecif
viral
replic
vivo
fit
pathogenesi
one
talk
present
integras
key
target
newli
develop
antiretrovir
drug
highresolut
cryoem
analysi
demonstr
assembl
multimer
structur
monom
size
form
intasom
structur
mediat
chromosom
integr
resolut
activ
site
reveal
strand
transfer
inhibitor
drug
target
well
potenti
new
structur
target
nextgener
inhibitor
anoth
talk
report
human
leukocyt
antigen
hla
haplotyp
associ
control
viremia
diseas
progress
caucasian
african
popul
poorli
repres
peopl
japanes
descent
research
team
found
found
approxim
japanes
individu
associ
significantli
lower
viral
load
increas
cell
count
addit
natur
killer
nk
cell
receptor
killer
cell
immunoglobulinlik
receptor
kir
may
also
contribut
control
japanes
individu
suggest
cytotox
lymphocyt
ctl
nk
respons
play
import
role
control
hiv
diseas
progressionreoviru
talk
featur
reoviru
revers
genet
system
establish
transfect
cell
via
plasmid
code
segment
reoviru
genom
major
develop
reoviru
fieldhepat
b
hbv
host
nataurochol
cotransport
polypeptid
ntcp
protein
found
essenti
compon
hbv
infect
liver
discuss
variant
ntcp
invers
associ
hbv
pathogenesi
cirrhosi
ntcp
sequenc
also
determin
host
rangezika
talk
show
dengu
antibodi
level
appear
determin
suscept
zikv
infect
high
dengu
titer
protect
lower
titer
enhanc
infect
infecti
diseas
final
talk
session
dr
georg
fu
gao
figur
highlight
key
element
china
year
experi
infecti
diseas
control
patriot
health
campaign
includ
govern
commit
public
educ
infecti
diseas
control
approach
could
potenti
appli
part
world
session
hepat
viru
infect
liver
cancer
provid
research
updat
molecular
virolog
immunolog
hbv
host
factor
relat
hepat
viru
infect
genet
landscap
virusassoci
hepatocellular
carcinoma
hcc
integr
genom
identifi
driver
human
liver
cancer
chemicalvir
interact
aflatoxin
hbv
induct
hcc
antibodi
therapeut
target
treatment
liver
cancer
extens
clinic
network
patient
china
random
clinic
trial
conduct
studi
new
treatment
strategi
chronic
hbv
infect
involv
nucleotid
analog
revers
transcriptas
inhibitor
peginterferon
ongo
effort
prevent
transmiss
hbv
shortterm
antivir
therapi
tenofovir
disoproxil
fumar
late
pregnanc
report
significantli
lower
hbv
transmiss
rate
compar
control
group
session
also
includ
discuss
host
factor
relat
hepat
viru
infect
use
genomewid
associ
studi
gwa
genet
analysi
use
gwa
identifi
host
factor
variou
human
multifactori
diseas
well
interferon
ifn
lambda
drug
respons
hla
ii
gene
suscept
chronic
hbv
infect
chb
frequenc
hladp
risk
allel
high
asian
popul
wherea
frequenc
hladp
protect
allel
high
european
popul
find
could
explain
high
incid
chb
asian
countri
suggest
host
genet
factor
import
viral
infect
anoth
talk
outlin
genom
epigenom
associ
hbvrelat
liver
cancer
use
data
obtain
whole
genom
bisulf
sequenc
whole
genom
sequenc
clonal
hbv
integr
preferenti
occur
inact
chromatin
region
massiv
rearrang
detect
integr
hbv
genom
neg
correl
exist
hbv
rearrang
number
total
somat
mutat
number
observ
could
use
understand
progress
hbvrelat
liver
cancer
note
liver
cancer
includ
hcc
cholangiocarcinoma
second
lead
caus
cancer
death
total
cancer
death
signific
burden
low
middleincom
countri
asia
subsaharan
africa
etiolog
factor
associ
hcc
includ
infect
hbv
exposur
high
level
aflatoxin
diet
hcvassoci
hcc
becom
rapidli
rise
solid
tumor
unit
state
japan
develop
highli
effect
drug
cure
hcv
infect
major
advanc
hope
diminish
role
hcv
liver
cancer
ongo
clinic
investig
defin
util
cell
surfac
proteoglycan
differenti
express
hcc
promis
antibodi
therapeut
treat
liver
cancer
session
focus
vaccin
seven
present
current
state
futur
landscap
vaccin
develop
technolog
promis
candid
clinic
outcom
promin
viral
infecti
diseas
dengu
zikv
respiratori
syncyti
viru
rsv
infect
hivaid
influenza
viru
handfootandmouth
diseas
hfmd
chikungunya
dengu
descript
dengu
vaccin
target
product
profil
overview
experiment
liveattenu
dengu
vaccin
develop
primarili
nation
institut
allergi
infecti
diseas
niaid
found
safe
protect
viru
challeng
studi
provid
ongo
phase
clinic
trial
brazil
also
discussedzika
overview
promis
experiment
singledos
liveattenu
zika
vaccin
evalu
nonhuman
primat
present
found
prevent
infect
achiev
protect
immun
within
day
postvaccinationrespiratori
syncyti
viru
rsv
infect
global
diseas
burden
rsv
need
one
rsv
vaccin
target
differ
age
popul
describ
also
overview
rsv
vaccin
current
clinic
develop
vaccinelik
particl
liveattenu
vectorbas
vaccin
discussedhivaid
talk
summar
find
cohort
studi
individu
identifi
acut
hiv
infect
bangkok
thailandinfluenza
detail
descript
univers
influenza
viru
vaccin
strategi
base
conserv
stalk
domain
hemagglutinin
presentedhandfootandmouth
diseas
hfmd
epidemiolog
baselin
hfmd
caus
multipl
serotyp
enteroviru
china
implic
vaccin
develop
discussedchikungunya
present
describ
versatil
advantag
measl
vector
vaccin
platform
phase
clinic
safeti
immunogen
measlesvector
chikungunya
vaccin
question
answer
session
focus
identif
correl
protect
evalu
vaccin
candid
immunocompromis
popul
antibodi
enhanc
stabil
attenu
vaccin
strain
last
plenari
session
includ
three
present
address
new
approach
defin
protect
immun
drug
discoveri
noroviru
highresolut
structur
analysi
viral
protein
provid
platform
ration
drug
design
noroviru
better
understand
innat
immun
could
lead
new
approach
vaccin
deliveri
new
protein
deliveri
system
also
introduc
may
potenti
becom
compon
needleless
vaccin
candidatezikv
structur
biolog
zikv
protein
suggest
potenti
drug
target
nonstructur
nonstructur
viral
protein
structur
could
provid
inform
host
interact
protect
antibodi
recognit
well
potenti
drug
target
site
structur
analysi
need
confirm
function
data
demonstr
drug
candid
dengu
viru
would
effect
zikv
infect
tolllik
receptor
mechan
control
innat
immun
respons
nucleic
acid
present
pathophysiolog
role
nucleotidesens
inflammatori
disord
possibl
way
might
induc
antivir
immun
respons
discuss
aid
panel
immunolog
board
conven
joint
meet
januari
cochair
dr
thoma
hope
northwestern
univers
usa
tetsuro
matano
univers
tokyon
institut
infecti
diseas
japan
secretariat
dr
david
mcdonald
niaid
usa
dr
maureen
goodenow
director
nih
offic
aid
research
usa
open
meet
overview
aid
research
fund
nih
emphas
import
basic
research
support
clinic
approach
prevent
treatment
cure
hivaid
session
clinic
impact
hiv
asiapacif
region
featur
report
hivaid
mongolia
vietnam
thailand
session
hiv
molecular
virolog
featur
talk
focus
cell
molecular
biolog
hiv
session
hiv
host
cell
microbiom
interact
includ
present
host
cell
factor
impact
hiv
assembl
entri
immun
respons
well
potenti
new
sourc
latent
infect
cell
infect
individu
final
session
titl
mucos
immunolog
vaccin
respons
includ
discuss
mucos
immunolog
intestin
virom
immun
control
herpesvirus
talk
viral
diseas
highlight
common
virus
like
hiv
target
mucos
site
transmiss
replic
emphas
import
crossdisciplinari
studi
viral
pathogenesi
vaccin
develop
discuss
also
focus
tcell
nk
cell
respons
hiv
strategi
perturb
lymphoid
tissu
architectur
flush
residu
latent
infect
cell
follicular
sanctuari
site
partner
immunolog
board
particularli
appreci
focu
mucos
intestin
immunolog
virolog
diseas
highli
relev
hiv
dr
hiroshi
kiyono
univers
tokyo
japan
immunolog
board
conclud
panel
meet
remembr
moment
silenc
commemor
dr
bonni
mathieson
pass
away
januari
dr
mathieson
program
offici
niaid
oar
year
touch
live
countless
research
scientist
around
globe
ari
panel
meet
took
place
januari
chair
dr
keigo
shibayama
nation
institut
infecti
diseas
japan
florian
krammer
icahn
school
medicin
mount
sinai
usa
secretariat
dr
kristina
lu
niaid
usa
meet
session
focus
viral
respiratori
diseas
respiratori
syncyti
viru
rsv
middl
east
respiratori
syndrom
coronaviru
merscov
coronaviru
antivir
therapeut
transmiss
pathogenesi
immun
influenza
influenza
viru
vaccin
inhibitor
main
object
ari
panel
meet
discuss
recent
research
advanc
viral
acut
respiratori
infect
establish
collabor
share
resourc
amongst
panel
member
colleagu
ari
panel
meet
featur
outstand
present
mostli
novel
unpublish
data
follow
activ
construct
discuss
deem
huge
success
continu
bacteri
acut
respiratori
infect
robust
discuss
interact
occur
panel
member
audienc
sever
collabor
develop
cancer
panel
meet
chair
dr
edward
l
trimbl
nation
cancer
institut
nci
usa
tohru
kiyono
nation
cancer
center
ncc
japan
secretariat
dr
mari
ricciardon
nci
usa
yukari
totsuka
ncc
japan
panel
meet
conven
five
session
overview
hepat
liver
cancer
molecular
biolog
liver
cancer
nonsurg
treatment
liver
cancer
earli
detect
liver
cancer
summari
discuss
next
step
panel
meet
particip
express
strong
interest
develop
research
consortium
address
prevent
screen
earli
detect
manag
liver
cancer
intend
form
work
group
nation
cancer
institut
nci
ame
academ
research
develop
research
resourc
includ
clinic
databas
tissu
biobank
foster
stronger
research
collabor
topic
mutual
interest
hepat
panel
new
approach
hepat
b
viru
hbv
therapi
chair
dr
takaji
wakita
nation
institut
infecti
diseas
japan
christoph
walker
nationwid
children
hospit
usa
rajen
koshi
niaid
usa
secretariat
keynot
lectur
dr
raymond
chung
massachusett
gener
hospit
usa
kick
twoday
meet
discuss
current
understand
cure
chronic
hepat
b
challeng
complet
elimin
hbv
stabl
selfperpetu
replic
intermedi
hbv
dna
panel
meet
includ
four
session
chronic
hepat
b
problem
explor
new
treatment
marker
function
cure
chronic
hepat
b
preclin
anim
model
test
hbv
cur
therapi
regul
hbv
replic
new
target
hbv
therapi
addit
panelist
present
poster
present
earlystag
investig
hepat
panel
meet
featur
except
present
collabor
discuss
success
outcom
reconven
viral
diseas
panel
chair
dr
richard
kuhn
purdu
univers
usa
jiro
arikawa
hokkaido
univers
graduat
school
medicin
japan
secretariat
dr
eun
chung
park
niaid
usa
panel
meet
focus
follow
session
topic
hemorrhag
virus
includ
ebola
lassa
sever
fever
thrombocytopenia
syndrom
viru
sftsv
highli
pathogen
recent
emerg
viru
asian
countri
includ
japan
korea
china
enter
virus
includ
noroviru
rotaviru
polioviru
viru
caus
hand
foot
mouth
diseas
southeast
asian
countri
arbovirus
includ
dengu
sftsv
chikungunya
virus
rabi
viru
includ
aspect
epidemiolog
pathogenesi
structur
biolog
anim
model
vaccin
antivir
develop
human
challeng
model
dengu
viru
signific
present
juniorearlystag
career
scientist
discuss
meet
robust
due
activ
particip
engag
discuss
notabl
present
earlystag
investig
select
abstract
submiss
includ
talk
clinic
trial
investig
vaccin
call
agsv
mosquito
saliva
peptid
proven
effect
vaccin
protect
mosquitoborn
viral
infect
anoth
present
broadspectrum
antivir
peptid
shown
activ
zika
viru
given
post
infect
anim
model
viral
diseas
panel
reconven
registr
intern
confer
emerg
infecti
diseas
pacif
rim
provid
opportun
scientist
public
health
expert
differ
countri
area
includ
australia
china
hong
kong
india
iraq
japan
mongolia
nepal
singapor
taiwan
thailand
unit
kingdom
usa
vietnam
come
togeth
interact
network
discuss
scientif
develop
inform
viral
diseas
import
asiapacif
region
global
intent
new
enhanc
product
research
collabor
expand
knowledg
could
lead
prevent
infecti
diseas
cancer
program
continu
evolv
engag
scientist
region
specif
focus
encourag
foster
collabor
youngearlystag
career
femal
scientist
around
region
eid
conven
hanoi
vietnam
februari
local
host
ministri
health
vietnam
focu
confer
bacteri
parasit
diseas
inform
go
furthermor
program
also
continu
foster
research
capac
earlystag
investig
provid
opportun
femal
investig
joint
research
call
propos
fund
niaid
ame
infecti
diseas
preval
asian
countri
third
round
joint
collabor
research
call
propos
open
octob
result
announc
may
summari
confer
provid
updat
current
statu
infecti
diseas
pacif
rim
region
includ
inform
new
emerg
virus
like
avian
influenza
viru
sftsv
cchfv
zika
well
press
public
health
problem
includ
hepat
dengu
hiv
